Latest news with #GlobalNewswire
Yahoo
4 days ago
- Health
- Yahoo
EAACI Launches Global Antibiotic Allergy Awareness Campaign at EAACI Congress 2025
ZURICH, Aug. 15, 2025 (GLOBE NEWSWIRE) -- EAACI has launched its Antibiotic Allergy Awareness Campaign during its 2025 Congress in Glasgow. The initiative begins a global effort to address mislabelling and its link to antimicrobial resistance (AMR). A Global Call to Action Antibiotic allergy mislabelling affects millions worldwide. Inaccurate labels lead to avoidance of first-line treatments and overuse of second-line antibiotics, fuelling AMR. EAACI calls on all stakeholders to promote accurate diagnosis and responsible antibiotic use. 'We are launching a movement — not a moment,' said Maria Torres, EAACI President. 'Too many lives are impacted by unverified allergy labels that limit treatment options and worsen health outcomes. This campaign builds momentum to correct labels, improve safety, and preserve antibiotics for future generations. Correcting labels means saving lives — now and in the future.' The Campaign's Objectives: Raise awareness about the dangers of incorrect antibiotic allergy labels Empower patients and healthcare professionals with tools and training Promote evidence-based allergy evaluation protocols Encourage rational antibiotic prescribing to protect long-term efficacy Breaking Down the Barriers Many patients carry outdated, unverified, or self-reported allergy labels, reducing treatment options and increasing risk. The campaign tackles these issues through education, training, and advocacy. Resources to Drive Change A central feature of the campaign is a short educational video explaining antibiotic allergy and why correct labels matter. The Promotional Kit 2025 offers tools to amplify the campaign across all platforms. Join the Movement Launched under the slogan 'Correct Labels, Better Lives,' the campaign invites professionals, educators, institutions, and individuals to join the global awareness effort. Together, we can protect the effectiveness of antibiotics. Explore the campaign and download resources: About EAACI The European Academy of Allergy and Clinical Immunology (EAACI) is Europe's largest professional association in the field, committed to advancing research and care for those affected by allergic diseases. Learn more: Contact: communications@ | +41 44 205 55 33 A photo accompanying this announcement is available at in to access your portfolio
Yahoo
10-07-2025
- Business
- Yahoo
Companies Like Pfizer Inc (PFE) are Boosting the Cannabis Light Market
Pfizer Inc. (NYSE:PFE) is one of the . On July 1, GlobalNewswire reported that the Cannabis Light Market is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.6% from 2025 to 2030. This is because companies like Pfizer Inc. (NYSE:PFE) have entered the industry. In 2021, Pfizer Inc. (NYSE:PFE) entered the medical cannabis sector by acquiring Arena Pharmaceuticals for $6.7 billion. The report highlighted that the industry is rapidly evolving due to increased legalization and cultivation activities around the globe. This has led to key pharmaceutical companies like Pfizer Inc. (NYSE:PFE) to forge partnerships to maximize the efficient use of cannabis using advanced lighting techniques. A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution. Pfizer Inc. (NYSE:PFE) is an international biopharmaceutical company that researches, develops, manufactures, and sells medicines and vaccines. Its products cover a wide range of health areas, including oncology, primary care, and specialty care. While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
